Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.
Antibacterial chemotherapy
Carbapenem-sparing agents
Cefoxitin
Extended-spectrum beta-lactamase
Healthcare-associated pneumonia
Intensive care
Population pharmacokinetics
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
28
05
2022
accepted:
01
09
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
30
9
2022
Statut:
epublish
Résumé
Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and emergence of cephamycin-resistance. Forty-one patients were included in this study, mainly with ESBL-PE pneumonia (35 patients, 85%). Cefoxitin was administered during a median [interquartile range (IQR)] duration of 5 [4-7] days. Cefoxitin serum concentrations strongly depended on renal function. Target serum concentration (> 5 × minimum inhibitory concentration (MIC) 24 h after cefoxitin onset was obtained in 34 patients (83%), using a median [IQR] daily dose of 6 [6-6] g with continuous administration. The standard dosage of 6 g/24 h was not sufficient to achieve the PK/PD target serum concentration for MIC up to 4-8 mg/L, except in patients with severe renal impairment and those treated with renal replacement therapy. Treatment failure occurred in 26 cases (63%), among whom 12 patients (29%) died, 13 patients (32%) were switched to alternative antibiotic therapy and 11 patients (27%) presented with relapse of infection with the same ESBL-PE. Serious adverse events attributed to cefoxitin occurred in 7 patients (17%). Acquisition of cephamycin-resistance with the same Enterobacterales was identified in 13 patients (32%), and was associated with underdosage. Continuous administration of large doses of cefoxitin appears necessary to achieve the PK/PD target in patients with normal renal function. Renal status, MIC determination and therapeutic drug monitoring may be useful for treatment individualization in this setting. The treatment failure rate was 63%. The cefoxitin safety profile was favorable, but we observed a high rate of cephamycin-resistance emergence.
Sections du résumé
BACKGROUND
BACKGROUND
Cefoxitin is active against some extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE), but has not been evaluated so far in the intensive care unit (ICU) settings. Data upon its pharmacokinetics (PK), tolerance and efficacy in critical conditions are scanty. We performed a retrospective single-center study in a university hospital medical ICU, in subjects presenting with cefoxitin-susceptible ESBL-PE infection and treated with cefoxitin. The primary aim was to determine cefoxitin PK. Secondary endpoints were efficacy, tolerance, and emergence of cephamycin-resistance.
RESULTS
RESULTS
Forty-one patients were included in this study, mainly with ESBL-PE pneumonia (35 patients, 85%). Cefoxitin was administered during a median [interquartile range (IQR)] duration of 5 [4-7] days. Cefoxitin serum concentrations strongly depended on renal function. Target serum concentration (> 5 × minimum inhibitory concentration (MIC) 24 h after cefoxitin onset was obtained in 34 patients (83%), using a median [IQR] daily dose of 6 [6-6] g with continuous administration. The standard dosage of 6 g/24 h was not sufficient to achieve the PK/PD target serum concentration for MIC up to 4-8 mg/L, except in patients with severe renal impairment and those treated with renal replacement therapy. Treatment failure occurred in 26 cases (63%), among whom 12 patients (29%) died, 13 patients (32%) were switched to alternative antibiotic therapy and 11 patients (27%) presented with relapse of infection with the same ESBL-PE. Serious adverse events attributed to cefoxitin occurred in 7 patients (17%). Acquisition of cephamycin-resistance with the same Enterobacterales was identified in 13 patients (32%), and was associated with underdosage.
CONCLUSION
CONCLUSIONS
Continuous administration of large doses of cefoxitin appears necessary to achieve the PK/PD target in patients with normal renal function. Renal status, MIC determination and therapeutic drug monitoring may be useful for treatment individualization in this setting. The treatment failure rate was 63%. The cefoxitin safety profile was favorable, but we observed a high rate of cephamycin-resistance emergence.
Identifiants
pubmed: 36175707
doi: 10.1186/s13613-022-01059-9
pii: 10.1186/s13613-022-01059-9
pmc: PMC9522958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90Informations de copyright
© 2022. The Author(s).
Références
Int J Antimicrob Agents. 2019 May;53(5):547-552
pubmed: 30742956
J Antimicrob Chemother. 2006 Nov;58(5):1074-7
pubmed: 16971415
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:82-9
pubmed: 18154531
Ther Adv Infect Dis. 2018 Nov 13;6:2049936118811053
pubmed: 30891241
Med Mal Infect. 2012 Mar;42(3):126-8
pubmed: 22341663
Braz J Microbiol. 2013 Oct 30;44(2):435-42
pubmed: 24294234
Antimicrob Agents Chemother. 2014 Aug;58(8):4899-901
pubmed: 24777104
Nephron. 1976;16(1):31-41
pubmed: 1244564
Antimicrob Agents Chemother. 1981 Dec;20(6):741-6
pubmed: 7325641
BMC Infect Dis. 2016 Aug 18;16(1):427
pubmed: 27538488
Int J Infect Dis. 2013 Mar;17(3):e159-63
pubmed: 23140947
Indian J Med Microbiol. 2005 Jan;23(1):20-3
pubmed: 15928416
Clin Infect Dis. 2020 Nov 5;71(8):e331-e337
pubmed: 31859352
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Am J Surg. 1988 May 31;155(5A):81-5
pubmed: 3287974
Infect Dis (Lond). 2015;47(11):789-95
pubmed: 26136072
Ther Drug Monit. 2012 Aug;34(4):467-76
pubmed: 22722776
Int J Infect Dis. 2014 Dec;29:91-5
pubmed: 25461239
Intensive Care Med. 2015 Jul;41(7):1181-96
pubmed: 26077053
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59
pubmed: 30675420
FEMS Microbiol Lett. 2000 Sep 15;190(2):181-4
pubmed: 11034276
Med Mal Infect. 2018 Aug;48(5):327-358
pubmed: 29759852
Antimicrob Agents Chemother. 1977 Mar;11(3):427-34
pubmed: 855997
Intensive Care Med. 2020 Jun;46(6):1127-1153
pubmed: 32383061
Am J Hosp Pharm. 1979 Jan;36(1):33-8
pubmed: 31790
Rev Infect Dis. 1979 Jan-Feb;1(1):233-9
pubmed: 400937
Ann Intensive Care. 2017 Dec;7(1):13
pubmed: 28155050
Antimicrob Agents Chemother. 2015 Sep;59(9):5107-13
pubmed: 26100708
Eur J Clin Pharmacol. 2012 May;68(5):735-45
pubmed: 22246211
J Hosp Med. 2011 Jan;6 Suppl 1:S16-23
pubmed: 21225946
Rev Mal Respir. 2017 Dec;34(10):1098-1113
pubmed: 28688757
J Clin Microbiol. 1997 Feb;35(2):508-10
pubmed: 9003629
Antibiotics (Basel). 2020 Dec 26;10(1):
pubmed: 33375237
Antimicrob Agents Chemother. 1981 Jan;19(1):18-21
pubmed: 7247357
J Hosp Infect. 2018 Mar;98(3):247-252
pubmed: 29222035
Rev Infect Dis. 1979 Jan-Feb;1(1):90-8
pubmed: 318227
Med Mal Infect. 2016 Jun;46(4):215-9
pubmed: 27210283
Crit Care Med. 2017 Apr;45(4):705-714
pubmed: 28157141
Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):553-563
pubmed: 27815778
Drug Intell Clin Pharm. 1983 Nov;17(11):816-8
pubmed: 6641504
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Hosp Infect. 2013 Aug;84(4):294-9
pubmed: 23846237
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Antimicrob Agents Chemother. 1977 Jan;11(1):84-7
pubmed: 319753
Antimicrob Agents Chemother. 1984 Sep;26(3):343-6
pubmed: 6508264
Am J Respir Crit Care Med. 2009 Nov 1;180(9):896-902
pubmed: 19661243
Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S72-81
pubmed: 16355320